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Shehzaad Joomye1, Donglai Yan1, Haiyun Wang1, Guoqiang Zhou2 and Guolin Wang1*Abstract
Background: We devised this study to quantify the effect of age on the consumption of cisatracurium under
general anaesthesia, using a computer controlled closed loop infusion system. We further investigated this effect
on, sufentanil and propofol consumption.
Methods: 74 patients of physical status I and II, requiring general anaesthesia for elective abdominal surgery, were
assigned to three groups. Patients in group 1 were aged from 20 to 45, group 2 were from 46 to 64, and group 3 above
65 years old. General Anesthesia was maintained with propofol and muscle paralysis was maintained using a closed-loop
computer controlled infusion of cisatracurium. For analgesia, intermittent bolus of sufentanil 10 μg was given.
Results: Cisatracurium consumption in group 1, 2 and 3 were 1.8 ± 0.3, 1.6 ± 0.4 and 1.3 ± 0.4 μg/kg/min respectively.
There was significant difference of cisatracurium consumption between group 1 and 3 (P = 0.002), and the consumption
of cisatracurium in group 3 was less as compared with group 2 (P = 0.04). The average recovery index of patients in
group 1, 2 and 3 were 8.8 ± 2.6, 11.5 ± 2.9 and 12.7 ± 2.5 minutes respectively. There were difference between group 1
and 2 (P = 0.02). As compared with group 1, the recovery index was still longer in group 3 (P = 0.001). Patients in group 1,
2 and 3 consumed an average sufentanil 0.4 ± 0.1, 0.4 ± 0.1 and 0.3 ± 0.1 μg/kg/hr, respectively. There were statistical
significant between group 1 and 3 (P < 0.0001), and the same trend was found between group 2 and 3 (P = 0.03). The
Consumption of propofol in group 1, 2 and 3 were 5.1 ± 0.4, 4.3 ± 0.6 and 3.1 ± 0.5 mg/kg/hr. The difference in the
propofol consumption was found statistically significant when comparing between any two groups.
Conclusion: We concluded that the sensitivity of anesthetic agents increased with age. Less medication was required to
achieve a desirable effect in older patients specially those above 65 years of age, and the drug effect was prolonged.
Trial registration: ClinicalTrials.gov Identifier: NCT01785446.
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PropofolBackground
Aging is a universal and progressive physiologic process
characterized by decline end-organ reserve, decrease func-
tional capacity, increasing imbalance of homeostatic mech-
anisms, and an increasing incidence of pathologic process
[1]. With the consideration on the daily increase of surgery
on elderly patients, proper adjustment of drug dosage is* Correspondence: wang_guolin@hotmail.com
1Department of Anaesthesiology, Tianjin Medical University General Hospital,
Tianjin Research Institute of Anaesthesiology, No. 154 Anshan Road, Heping
District, 300052 Tianjin, China
Full list of author information is available at the end of the article
© 2014 Joomye et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orrequired for safe recovery from general anesthesia. To
achieve this goal, anesthesiologists should minimize the
dosage of anesthetics to avoid the side effect of drug re-
sidual, while maintains adequate intra-operative uncon-
sciousness, analgesia and paralysis for older patients.
Over-dosage of neuromuscular blocking agents especially
in elderly patients can lead to delay in recovery and post-
operative residual curarization [2]. Accurate administra-
tion of such drugs minimizes such effect. The closed-loop
infusion is a very sensitive technique in providing stable
surgical operating conditions, while diffusing minimal
amount of drug to maintain relaxation at a given level [3].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ately its consumption but also to prevent side effects
due from over dosage. In this study, we determined the
intra-operative consumption of cisatracurium infusion
and its recovery index using a closed loop computer
controlled system in different aged groups. We also cal-
culated sufentanil and propofol consumption in these
groups. The implication of this study may be reassuring
to the clinician the effect of age on the profile of muscle
relaxant, thus minimize the over dosage and prolonged
recovery time.
Methods
The study was approved by our hospital ethical commit-
tee: Board Name; Tianjin Medical University General
Hospital Ethics Committee, Board Affiliation; Tianjin
Medical University General Hospital Ethics Committee.
(Phone: +86-22-60361517). Approval number: 201252.
It was conducted according to the guidelines of the
above mentioned ethical requirements, and all patients
gave written consent prior the study. Experimental Design
and Groups Patients scheduled for elective abdominal
general surgery under general anaesthesia were assigned
to 3 groups. All patients were of ASA status I and II, and
they were all required to give consent before starting the
study. Group 1 were aged from 20 to 45, group 2 from 46
to 64 and group 3 were 65 and above. The exclusion criteria
were as follows: patients with neuromuscular junction dis-
orders, myopathies, peripheral neuropathies, encephalop-
athies, abnormal renal or liver laboratory function test and
any patients with flaccid paralysis [4-6] (Additional file 1).
For accurate comparison of drug consumption between
groups, all patients must have same induction protocol:
midazolam 0.05 mg/kg, sufentanil 0.3 μg/kg, etomidate
0.2 mg/kg and a bolus dose of cisatracurium 0.15 mg/kg
which was given by the computerized closed loop infusion
system (CLMSRI-I, Guangxi VERYARK Technology Co.,
Ltd.). All patients received propofol infusion titrated to
the clinical situation in a range of 4.5 to 7.5 mg/kg/hr
(75–125 μg/kg/min) according to the BIS value of 40–60.
Hypotension, defined as systolic blood pressure below
80 mmHg or mean arterial pressure below 60 mmHg for
more than 5 minutes, was treated by reducing propofol in-
fusion by 0.6 mg/kg/hr (10 μg/kg/min), but within the
range of 4.5 to 7.5 mg/kg/hr. Additional intravenous fluids
were given as deemed appropriate. Response was reas-
sessed at 5 minute intervals and the above measures con-
tinued until stabilization of blood pressure. Hypertension,
defined as systolic blood pressure above 150 mmHg or
mean arterial pressure above 95 mmHg for more than
5 minutes, was treated by giving additional sufentanil
(10 μg) boluses. Sufentanil boluses (10 μg) were also given
to patients in all groups when there was an increase in the
heart rate by more than 20 beats per minute or meanarterial pressure by more than 15% indicating lightening
of anaesthesia. Response was reassessed at 5 minute inter-
vals and the above measures repeated until stabilization.
During the whole procedure of anesthesia, the infusion
of cisatracurium and the monitoring of neuromuscular
block status were done by the computerized closed loop
infusion system (CLMSRI-I, Guangxi VERYARK Technol-
ogy Co., Ltd.). The degree of neuromuscular blockade was
assessed every 20 seconds. Surface electrodes were at-
tached over the ulnar nerve and over the first interosseus
muscle and the index finger [7]. The train-of-four (TOF)
sequence was used (2 Hz frequency, 100 ms pulse width),
the stimulus output being a rectangular wave with a
current of 0–70 mA. The machine calibrated automatic-
ally by searching for the optimal signal levels before set-
ting the supramaximal level. Control electromyographic
values were obtained after induction and following this, a
stable baseline calibration signal was awaited and a second
calibration was performed approximately 10 minutes after
induction of anesthesia. During this period patients were
ventilated manually with a mask. The degree of neuro-
muscular blockade was defined as the ratio of the meas-
urement of the first twitch in the TOF sequence to the
corresponding control value. The desired level of neuro-
muscular block (i.e., the set point) was set to 90% (the first
twitch (T1) in the TOF sequence = 10% from control). Pa-
tients were intubated when the T1% dropped below 10%
as compared with baseline value.
After obtaining a stable calibration signal, a bolus dose of
cisatracurium 0.15 mg/kg was administered. We used the
ideal body weight (IBW), as defined by Devine’s equation,
for the calculation of the dose of cisatracurium [8]. Tra-
cheal intubation was performed and the patients were
mechanically ventilated using either of the above men-
tioned gas mixtures. Bolus administration of cisatracurium
was followed by infusion of cisatracurium by a model-
driven closed-loop feedback system as described previously
[9]. The infusion rate maintained itself at the low rate of
0.2 μg/kg/min as long as the T1 response was less than
10%, which would automatically increase to 5.0 μg/kg/min
when T1 is above 10%. The rate of infusion would fall back
to 0.20 μg/kg/min when the T1 is less than 10%. Once the
bolus dose was given after which the infusion rate was set
at 0.20 μg/kg/min. Patients were intubated when the T1%
dropped below 10%. The degree of neuromuscular blockage
was assessed every 20 seconds throughout the procedure
using the TOF testing. The consumption of cisatracurium
was recorded in μg/kg/hr.
Propofol infusion was used in all patients for the mainten-
ance of anesthesia intraoperatively. The rate of infusion was
adjusted according to the BIS value (40–60). The total
amount of propofol used from induction to skin closure was
recorded and its consumption was calculated in mg/kg/hr
in each patient. Sufentanil consumption was calculated in








Number of patients 21 33 20
Age 38.0 ± 7.0 54.7 ± 4.5 73.6 ± 3.2
Weight 67.1 ± 8.6 67.6 ± 10.5 61.2 ± 14.4
BMI 24.3 ± 2.16 24.7 ± 3.2 21.8 ± 1.8
Male/Female 7/14 12/21 6/14
Cisatracurium consumption,
μg/kg/min
1.8 ± 0.3 1.6 ± 0.4 1.3 ± 0.4
Recovery index, minutes 8.8 ± 2.6 11.5 ± 2.9 12.7 ± 2.5
Sufentanil consumption, μg/kg/hr 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1
Propofol consumption, mg/kg/hr 5.1 ± 0.4 4.3 ± 0.6 3.1 ± 0.5
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stopped at skin closure. Furthermore, the linear regression
analysis was used to establish the relationship between cisa-
tracurium consumption and age.
After which the TOF monitoring was observed, and rever-
sal agents, neostigmine 40 μg/kg with atropine 0.15 mg/kg
[10], were given only when at least two twitches were
present according to TOF monitoring. The tracheal extuba-
tion was performed after full recovery from neuromuscular
block (TOF-ratio ≥ 0.90) [10], the monitoring of airway
patency, respiratory rate, continuous oxygen saturation,
blood pressure, and pulse were controlled in emergence
and recovery. Assessment of the neuromuscular function
was based on both physical examination and the TOF
monitor. The recovery index (RI), defined as the time re-
quired for T1 of the TOF to recovery from 25% to 75% of
baseline [11]. Patients would not leave the operating room
with the TOF ratio of less than 90%. Fully awake patients,
with stable vitals and ability to move all limbs were then
transferred to the Post-Anesthetic Care Unit (PACU) for
further monitoring. Patients were observed for at least
60 minutes in the PACU before sending back to the
ward. Patients should fulfill well defined criteria before
being sent back to wards, including [12]: fully conscious
oriented in time, space and person; able to maintain a
clear airway and exhibit effective protective reflexes;
able to lift head and hold up for more than 30 seconds;
bilateral firm hand grips and movement of all extrem-
ities; clear vision without nystagmus; respiration and
oxygenation returned to preoperative base level; stable
cardiovascular function on acceptable level with no un-
explained irregularity or uncontrolled bleeding; pain
and emesis properly controlled and analgesic or anti-
emetic regime prescribed.
Statistical analysis
The calculation of the number needed to find a difference
of at least 20% (group 1 or 2 vs group 3; the mean cisatra-
curium consumption of group 1 and 2 are larger than
1.6 μg/kg/min, and standard deviation ≈ 0.3) with an alpha
risk of 5% and a power (1-beta) of 80% shows that 20 pa-
tients are needed in each group. The SPSS Statistics17.0
software was used for the statistical analysis. All results
are given as mean ± SD. Test of normality was done for
each group and one-way ANOVA was used to compare
means between the 3 groups followed by Turkey test.
Results
Table 1 summarizes the demographic data and results of
the three groups. There was no significant difference in
gender, body mass index and BIS value within the groups.
The average consumption of cisatracurium in group 1,
2 and 3 were 1.8 ± 0.3, 1.6 ± 0.4 and 1.3 ± 0.4 μg/kg/min
respectively. Figure 1 demonstrates a box plot showingthe decreasing consumption of cisatracurium in the
three groups. There was significant difference of cisatra-
curium consumption between group 1 and 3 (P = 0.002),
and the consumption of cisatracurium in group 3 was
less as compared with group 2 (P = 0.04). The increase
in the sensitivity of cisatracurium with age was further
demonstrated by its increase in recovery index. The
average recovery index of patients in group 1, 2 and 3
were 8.8 ± 2.6, 11.5 ± 2.9 and 12.7 ± 2.5 minutes respect-
ively (Figure 2). There were difference between group 1
and 2 (P = 0.02). As compared with group 1, the recov-
ery index was still longer in group 3 (P = 0.001). We also
found a decrease in consumption of sufentanil with age
(Figure 3). Patients in group 1, 2 and 3 consumed an aver-
age sufentanil 0.4 ± 0.1, 0.4 ± 0.1 and 0.3 ± 0.1 μg/kg/hr, re-
spectively. There were statistical significant between group
1 and 3 (P < 0.0001), and the same trend was found be-
tween group 2 and 3 (P = 0.03). Figure 4 illustrates the
change in propofol consumption. The Consumption of
propofol in group 1, 2 and 3 were 5.1 ± 0.4, 4.3 ± 0.6 and
3.1 ± 0.5 mg/kg/hr. The difference in the propofol con-
sumption was found statistically significant when compar-
ing between any two groups.
To further confirm the relationship between cisatra-
curium consumption and age, we performed a linear re-
gression analysis. The linear regression model showed
an inverse and significant relationship between cisatra-
curium consumption and age (p <0.01).
For the unequal number of patients in three groups,
we randomly selected 20 patients from group 2 and rea-
nalyzed the statistical results, all these procedures re-
peated for three times. We still found the same results
as compared with the previous one.
Discussion
This study was designed to better appreciate the impact
of age in the consumption of cisatracurium with a closed
Figure 1 The changes in cisatracurium consumption in the
three groups. Group 1: patients aged from 20–45; group 2: aged
from 46–65; group 3: aged exceed 65. All results are given
as mean ± SD.
Figure 3 Sufentanil consumption in the three groups. Group 1:
patients aged from 20–45; group 2: aged from 46–65; group 3: aged
exceed 65. All results are given as mean ± SD.
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effect of age on the recovery index, and the consumption of
sufentanil and propofol. We noted a decrease in consump-
tion of cisatracurium with age, and there was a decrease of
26% in group 3 (older) as compared with group 1 (young
patient). A total number of 74 patients were investigated
and were divided into 3 groups according to their age. We
decided to have more than two groups to better appreciateFigure 2 The recovery index of the three groups. Group 1:
patients aged from 20–45; group 2: aged from 46–65; group 3: aged
exceed 65. All results are given as mean ± SD.the linear regression of consumption of drugs with age.
The pharmacodynamics of muscle relaxants are altered in
elderly patients since hepatic metabolism and renal clear-
ance decreases with age. We would expect that the effect of
cisatracurium would be unaffected with age since it is elimi-
nated by Hofmann degradation. But our results showed an
increase in the effect of cisatracurium with age. Besides the
renal and hepatic physiologic changes with age, there are
a number of other physiologic changes that accompany the
aging process, including decrease in total body water, de-
crease in lean body mass and muscle mass, increase inFigure 4 Propofol consumption in the three groups. Group 1:
patients aged from 20–45; group 2: aged from 46–65; group 3: aged
exceed 65. All results are given as mean ± SD.
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and decrease in cardiac reserve, which account for the
altered responses to muscle relaxants [13,14] in aged
patients. We might infer that a decrease in total body
water could lead to a smaller central compartment and
increased serum concentration after bolus dose admin-
istration of a drug. In addition the increase in body fat
might result in greater volume distribution, with the po-
tential to prolong the clinical effect of a given medica-
tion [15]. Furthermore it had been postulated by Cope
TM and colleagues that the effect of mivacurium was
enhanced in older patients due to a decrease of
plasma acetyl cholinesterase activity [16]. Sorooshian
SS et al., studies the pharmacodynamics and pharma-
cokinetics of cisatracurium in young and elderly
adults. They found that the plasma clearance of cisa-
tracurium was similar in young and the elderly group,
but the volume of distribution was significantly less
in the elderly which accounted for delayed response
of cisatracurium [17].
Atracurium which also undergoes Hofmann degradation
was also found by Kitts and colleagues [18] to have an in-
creasing effect in elderly patients. They concluded that the
pharmacokinetics, but not the pharmacodynamics, of atra-
curium differ significantly between elderly and young adults
which resulted in a slightly prolonged effect of neuromus-
cular blockade in elderly patients. Kisor et al. [19] found
that Hofmann clearance accounted for 77% of total body
clearance. Organ clearance was 23% of total body clearance.
Renal clearance, a component of organ clearance, was 16%
of total body clearance, whereas renal clearance of atracur-
ium accounted for 2% to 10% of the administered dose,
values slightly lower than those found for cisatracurium
[20]. Therefore, we think the deteriorating renal function
with ages also contributed to the longer effect of cisa-
tracurium in the older age groups. The average age in
group 3 is 73.6 ± 3.2 yr, In a review of Cope et al.,
they stated that the physiological changes such as the
decrease in cardiac output and muscle mass, an in-
crease in body fat and the deterioration in renal and
hepatic function, which could affect the pharmacokin-
etics of neuromuscular-blocking agents may not be-
come apparent clinically in healthy individuals until
the age of at least 75 years [16]. In our current study,
the average age in group 3 is 73.6 ± 3.2 yr, which is
close to the age they inferred.
We also demonstrated a decrease in consumption of
sufentanil by 32% in patients above 65 years of age as
compared to patients below 45. Similar results have also
been obtained in other studies. Shafer provided a com-
prehensive review of the pharmacology of sufentanil,
alfentanil, and fentanyl in elderly patients [15]. Sufenta-
nil, alfentanil and fentanyl were approximately twice as
potent in elderly patients. These findings were primarilyrelated to an increase in drain sensitivity to opioids with
age, rather than alterations in pharmacokinetics.
We further investigated the impact of patients’ age on
propofol consumption. Patients below 45 years of age con-
sumed an average of 5.1 ± 0.4 mg/kg/hr of propofol. Older
patients between 46 and 64 consumed 4.3 ± 0.6 mg/kg/hr,
and elderly patients above 65 consumed 3.1 ± 0.5 mg/kg/hr.
This showed a decrease of 39% in consumption between
group 1 and 3. For an explanation of the observed results,
both pharmacokinetic and pharmacodynamic mechanisms
must be considered, i.e. that a defined dose of propofol
produces higher drug concentrations in an elderly patient
and that the same propofol concentration produces a
more profound anaesthetic effect [15]. When comparing
the pharmacokinetics of a propofol bolus, Kirkpatrick and
colleagues [21] could demonstrate that mean propofol
blood concentrations tended to be higher in elderly (65–
80 yr) than in younger (18–35 yr) patients, best explained
by a significantly lower metabolic propofol clearance and a
smaller volume of the central compartment. Furthermore,
Schüttler and Ihmsen found a linear decrease of the propo-
fol elimination clearance in patients older than 60 yr [22].
These findings may be explained by a reduction of liver
function or liver blood flow in elderly patients [23], as the
propofol clearance has been characterized as liver blood
flow dependent [24]. For propofol pharmacodynamics, age-
related changes of brain function must be considered.
Comparing a 20- and a 90-yr-old individual, brain under-
goes an age-dependent weight reduction of approximately
10%, while the gray matter decreases more than the white
matter [25]. Concomitantly, the cell number of the frontal
cortex decreases by approximately 40% [26]. Our clinically
obtained data are supported by results of Schnider and col-
leagues [27] who, in a laboratory setting, reported that eld-
erly patients were more sensitive to hypnotic and EEG
effects of propofol than were younger persons.
Conclusions
In conclusion, we summarized that the sensitivity of cisatra-
curium increases with age of patients. Less cisatracurium
was required to achieve a desirable effect in elder population
with a closed loop infusion system. Even though the dose
decreases in the elder patients, a prolonged duration of ac-
tion of cisatracurium was observed among patients above
65 years of age. We also found that the consumption of pro-
pofol and sufentanil decrease in elderly as compared with
young adult and middle adult population. These implied for
the clinicians that older patients would need a downward
adjustment in medication dose during general anesthesia.Additional file
Additional file 1: CONSORT 2010 Flow Diagram.
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